UK Markets closed

e-Therapeutics plc (ETX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
16.48-0.42 (-2.51%)
At close: 03:49PM GMT

e-Therapeutics plc

4 Kingdom Street
Floor 4 Unit 4B Paddington Central
London W2 6BD
United Kingdom
44 20 4551 8888

Full-time employees39

Key executives

NameTitlePayExercisedYear born
Mr. Ahmad Ali MortazaviCEO & Director348kN/A1971
Mr. Michael Anthony Bretherton ACA, B.A.Acting Interim CFO & Director53kN/A1955
Dr. Laura Roca-Alonso Ph.D.Chief Operating & Bus. OfficerN/AN/AN/A
Mr. Alan Whitmore B.Sc., Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Sarah ClareDirector of Fin. & ComplianceN/AN/AN/A
Ms. Alison GallafentChief Intellectual Property OfficerN/AN/AN/A
Mr. Ankit SharmaHead of Software EngineeringN/AN/AN/A
Mr. Graham CraggsHead of Therapeutic DiscoveryN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.

Corporate governance

e-Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.